By identifying the association between thyroid hormone sensitivity and MetS risk, clinicians can consider evaluating thyroid function more comprehensively using indices like TFQI and FT3/FT4 ratio, rather than relying solely on traditional markers such as TSH, FT3, and FT4. This evidence concerns the gene TG and metabolic syndrome.